DexCom promotes Kevin Sayer to CEO post, while its diabetes collaborator Insulet makes multiple changes at the VP level. The Medical Imaging & Technology Alliance names policy director, and more.
Glucose monitoring systems firm DexCom Inc. has tapped its president and COO Kevin Sayer to be president and CEO, the firm said Jan. 5. Sayer succeeds Terry Gregg, who is transitioning to the role of executive chairman for DexCom after seven years in the top spot and nine years of service with the firm.
Sayer, who became DexCom’s president and COO in January 2013 after working as president for two years, has served as a board member since November 2007. Prior to this he...
Medtronic’s diabetes spin-out – a process likely to run up to 18 months and involve 20% IPO followed by a split-off for Medtronic shareholders – will allow firm to focus on higher-margin devices.
The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.
Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.
Apart from the reimbursement-driven turbulence in diagnostics, other aspects of Danaher’s China business are showing signs of resilience. Patient volumes remain strong and the company does not see evidence that the Chinese government is attempting to actively push Western suppliers out of its healthcare system.
